Registry for stage 2 type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tracks people with stage 2 type 1 diabetes to see how they do over time, either with or without treatment with a drug called TZIELD. It helps doctors learn more about the disease and the effects of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be living in the United States.
- You must have been diagnosed with stage 2 type 1 diabetes.
- You either plan to start TZIELD treatment soon, or have already started it within the last 6 months, or you have not been treated with TZIELD at all.
- You cannot have taken TZIELD for more than 6 months already.
- You cannot be currently in another clinical trial for an experimental drug (though you can be in other types of studies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches people with stage 2 type 1 diabetes who either get teplizumab or not, to compare their real-world experiences. It helps researchers learn how the drug affects daily life.
This study follows people who have already received teplizumab (a treatment to delay type 1 diabetes) to see how they do over time. It aims to understand the long-term effects in routine care.
This Phase 1/2 study tests whether CELZ-201 is safe and can help the body keep making some of its own insulin in people who were recently diagnosed with type 1 diabetes. You may be eligible if your diabetes started within the past year and your tests show you still have some insulin-making activity.
This study looks at real-world outcomes in patients with type 1 diabetes who received teplizumab through managed access programs. It helps researchers understand how well the treatment works outside of a clinical trial setting.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
This Phase 2 study tests whether starting with cyclosporine and then giving low-dose IL-2 can better protect the body’s insulin-producing function after type 1 diabetes is diagnosed. It’s meant for people diagnosed very recently who have specific diabetes-related immune markers.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.